Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Transcript
What are some of the disparities we see in multiple myeloma treatment?
The disparities relate to the differences between clinical trials and real-world [outcomes]. So, in clinical trials we cherry picked really healthy patients. The treatment team is geared to treat until progression. The patients are also more likely to be going until progression on therapy. And there’s more radiologic screening, which might shorten the duration of treatment; conversely, patients might come off earlier because of biochemical progression due to rigorous testing.
So, when we go to the real world, we have patient factors where you may have patients who are older, have a lot of comorbidities that would not have been eligible for the study. And then patients might not get treated until progression because of either patient fatigue or physician or nursing fatigue in terms of continuing until progression. And, of course, if physicians aren’t checking rigorous [monoclonal] spikes, they might keep them on longer, they might keep them on even if patients have biochemical progression, but they don’t have clinical symptoms—they might continue on longer than a study would allow them to.
But in general, what we found was that treatment durations tend to be shorter in real world than in clinical trials, probably because of the patient comorbidities and the perhaps treatment team’s intention to treat to progression.
What treatment patterns in multiple myeloma have you seen by age and by region?
First of all, there’s not clear dominant treatment pattern in myeloma, neither by region, age, newly diagnosed, or relapsed. I think that’s one of the important findings from this. There’s a lot of heterogeneity in treatment across the world.
But what we do see in the US, the most commonly used induction regimen is VRd [bortezomib plus lenalidomide and dexamethasone] or RVd [lenalidomide plus bortezomib and dexamethasone], which is not used in Europe. We see more CyBorD [cyclophosphamide, bortezomib, and dexamethasone], VTd [bortezomib, thalidomide, and dexamethasone]. So, that’s a big regional difference.
Second thing is that triplets tend to be used more in newly diagnosed younger patients, transplant eligible. We see more doublet therapies in older patients and so those are some of the differences we see.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More